End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3222 USD | -2.36% |
|
+2.32% | -20.05% |
Jul. 08 | Tonix Pharmaceuticals Intends to Offer and Sell Shares of its Common Stock | CI |
Jul. 08 | Tonix Pharmaceuticals Plans Stock Offering; Shares Fall After-Hours | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 9.974 | 129.4 | 177.5 | 22.43 | 23.62 | 7.005 | - | - |
Enterprise Value (EV) 1 | 9.974 | 129.4 | 177.5 | 22.43 | 23.62 | 7.005 | 7.005 | 7.005 |
P/E ratio | -0.06 x | -1.23 x | -1.38 x | -0.12 x | -0.06 x | -0.02 x | -0.03 x | -0.05 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 3.04 x | 0.5 x | 0.39 x | 0.16 x |
EV / Revenue | - | - | - | - | 3.04 x | 0.5 x | 0.39 x | 0.16 x |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 1.33 | 29.9 | 77.5 | 288 | 1,832 | 9,833 | - | - |
Reference price 2 | 7,488 | 4,320 | 2,289 | 77.96 | 12.90 | 0.7124 | 0.7124 | 0.7124 |
Announcement Date | 3/24/20 | 3/15/21 | 3/14/22 | 3/13/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | 7.768 | 13.92 | 17.78 | 44.59 |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -28.83 | -50.51 | -92.31 | -112.1 | -118.4 | -80.37 | -91.94 | -78.67 |
Operating Margin | - | - | - | - | -1,523.94% | -577.54% | -516.99% | -176.42% |
Earnings before Tax (EBT) 1 | -28.62 | -50.46 | -92.29 | -110.2 | -116.7 | -117.1 | -123.1 | -124.5 |
Net income 1 | -31.09 | -52.17 | -92.29 | -116.9 | -116.7 | -79.76 | -91.09 | -77.82 |
Net margin | - | - | - | - | -1,501.78% | -573.18% | -512.21% | -174.52% |
EPS 2 | -123,712 | -3,520 | -1,664 | -654.0 | -219.2 | -30.56 | -22.08 | -13.92 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/24/20 | 3/15/21 | 3/14/22 | 3/13/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | 3.989 | 3.779 | 2.482 | 3.35 | 3.475 | 3.95 | 4.1 | 4.65 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -29.56 | -26.44 | -23.34 | -29.59 | -32.73 | -33.9 | -29 | -28.15 | -27.33 | -21.35 | -21.17 | -18.97 | -18.88 | - | - |
Operating Margin | - | - | - | - | - | - | - | -705.62% | -723.18% | -860.23% | -631.94% | -545.9% | -477.97% | - | - |
Earnings before Tax (EBT) 1 | -29.55 | -26.42 | -23.14 | -28.98 | -31.68 | -33 | -28.36 | -27.98 | -27.32 | -14.94 | -28.9 | -29.4 | -30.4 | - | - |
Net income 1 | -29.55 | -26.42 | -27.4 | -28.98 | -34.08 | -33 | -28.36 | -27.98 | -27.32 | -14.94 | -20.77 | -18.57 | -18.48 | - | - |
Net margin | - | - | - | - | - | - | - | -701.3% | -723% | -601.89% | -620% | -534.39% | -467.85% | - | - |
EPS 2 | -448.0 | -320.0 | -244.0 | -138.0 | -112.0 | -104.0 | -85.76 | -58.56 | 17.60 | -5.760 | -7.200 | -6.400 | -6.560 | -5.440 | -5.440 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/14/22 | 5/9/22 | 8/8/22 | 11/7/22 | 3/13/23 | 5/8/23 | 8/10/23 | 11/9/23 | 4/1/24 | 5/13/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/24/20 | 3/15/21 | 3/14/22 | 3/13/23 | 4/1/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.14% | 96.32B | |
+4.21% | 40.77B | |
-11.86% | 33.21B | |
+81.62% | 29.36B | |
-14.25% | 15.7B | |
-7.36% | 13.08B | |
-13.08% | 11.39B | |
+176.65% | 10.47B | |
-57.36% | 8.58B |
- Stock Market
- Equities
- TNXP Stock
- TNXP Stock
- Financials Tonix Pharmaceuticals